Reuters logo
8 months ago
BRIEF-ARIAD's brigatinib demonstrated 15.6 month systemic median progression-free survival in ALTA study
December 7, 2016 / 12:55 PM / 8 months ago

BRIEF-ARIAD's brigatinib demonstrated 15.6 month systemic median progression-free survival in ALTA study

1 Min Read

Dec 7 (Reuters) - ARIAD Pharmaceuticals Inc -

* ARIAD's investigational medicine brigatinib demonstrated 15.6 month systemic median progression-free survival in alta study

* 55 percent confirmed systemic objective response rate from study

* Analysis also demonstrated intracranial median progression-free survival (pfs) of 18.4 months

* Data are intended to be submitted to european medicines agency in early 2017 for marketing approval

* Initiated phase 3 alta 1l trial to assess efficacy and safety of brigatinib in comparison to crizotinib Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below